Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: First Quarter ended 31 March 2012
Announcement Date: 25 April 2012
GSK reported a return to sales growth for the first quarter of 2012, driven by performance in the US, Emerging Markets/Asia Pacific (EMAP), and Japan, which offset declines in Europe and the ViiV Healthcare division. The company continues to execute its strategy of divesting non-core Over-the-Counter (OTC) brands and investing in its R&D pipeline.
Key Financial Metrics
| Metric | Q1 2012 | Q1 2011 | CER Growth % |
|---|---|---|---|
| Turnover | £6,640m | £6,585m | +2% |
| Core Operating Profit | £2,071m | £2,044m | +3% |
| Core Operating Margin | 31.2% | 31.0% | N/A |
| Core Earnings Per Share (EPS) | 27.3p | 25.9p | +7% |
| Total EPS | 26.7p | 30.0p | -10% |
| Net Cash Inflow (Operating) | £1,012m | £987m | N/A |
| Free Cash Flow | £687m | £597m | +15% |
| Net Debt | £8,877m | £8,419m | N/A |
Material Changes vs. Prior Period
- Sales Growth: Total turnover increased 2% (CER). Pharmaceuticals and Vaccines grew 2%, while Consumer Healthcare grew 1% (7% excluding non-core OTC brands).
- Regional Performance: US Pharmaceuticals and Vaccines grew 9%, driven by Advair and new oncology products. Europe declined 6% due to government austerity measures and price cuts. EMAP grew 2% despite instability in the Middle East/Africa.
- Profitability: Core operating profit rose 3% to £2.1 billion, with margins improving to 31.2%. Total EPS fell 10% primarily due to the one-off profit from the Quest Diagnostics disposal in Q1 2011, which did not recur.
- Divestitures: Agreements were reached to divest non-core OTC brands with combined 2011 sales of approximately £370 million, expected to generate net cash proceeds of ~£690 million.
Guidance, Outlook, and Risks
- Outlook: GSK maintains its 2012 outlook for sales growth and a gradual expansion of core operating margins.
- Shareholder Returns: The Q1 dividend was increased 6% to 17p. Total share buybacks for 2012 are now expected to be £2-£2.5 billion, utilizing proceeds from OTC disposals.
- R&D Pipeline: Significant progress reported in Phase III assets for HIV (dolutegravir), melanoma (dabrafenib, trametinib), and diabetes (albiglutide). Four products are expected to complete Phase III registration studies in 2012.
- Risks: Continued economic pressure and political instability in key markets (Europe, Middle East/Africa). Pricing pressures on established products and generic competition remain significant headwinds. Legal provisions for disputes stand at £2.6 billion.
Investor Verification Checklist
- Core vs. Total EPS: Verify the impact of non-core items (restructuring, legal costs, asset disposals) on Total EPS, which declined 10% despite Core EPS growth of 7%.
- OTC Divestiture Timeline: Confirm the completion dates and final proceeds for the European and International non-core OTC brand sales expected in Q2 2012.
- Europe Pricing Pressure: Monitor the impact of government austerity measures and price cuts on the European Pharmaceuticals and Vaccines segment, which declined 6%.
- Legal Provisions: Review the £2.6 billion provision for legal and tax disputes and any potential for material increases in liability.
- Share Buyback Execution: Track the execution of the £2-£2.5 billion share repurchase program against free cash flow generation.